General commentary on drug therapy and drug risks in pregnancy

Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment: Third Edition

Volumn , Issue , 2015, Pages 1-23

  Peters, Paul ^a   Miller, Richard K ^b   Schaefer, Christof ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Birth defect; Dysmorphology; ENTIS; Epidemiology; Mothertobaby; OTIS; Pregnancy registries; Risk communication; Teratogen information services; Teratology; Thalidomide

Indexed keywords

EID: 84943277379     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-408078-2.00001-9     Document Type: Chapter

References (46)

1. Aitken R.J., Sawyer D. The human spermatozoon - not waving but drowning. Adv Exp Med Biol 2003, 518:85-98.
2. Barber C.V., Fantel A.G. The role of oxygenation in embryotoxic mechanisms of three bioreducible agents. Teratology 1993, 47:209-223.
3. Barker D.J.P. Mothers, Babies and Health in Later Life 1998, Churchill Livingstone, Edinburgh. 2nd edn.
4. Briggs G.G., Freeman R.K., Yaffe S.J. Classification of drugs for teratogenic risk: an anachronistic way of counseling: a reply to Merlob and Stahl. Birth Defects Res A 2003, 67:207-208.
5. Carney E.W., Scialli A.R., Watson R.E., et al. Mechanisms regulating toxicant disposition to the embryo during early pregnancy: an interspecies comparison. Birth Defects Res C Embryo Today 2004, 72:345-360.
6. Chamberlain G. ABC of antenatal care. Organisation of antenatal care. Br Med J 1991, 302:647-650.
7. Chermesh I., Eliakim R. Mesalazine-induced reversible infertility in a young male. Dig Liver Dis 2004, 36:551-552. Scopus Exact.
8. Colie C.F. Male mediated teratogenesis. Reprod Toxicol 1993, 7:3-9.
9. Committee on Developmental Toxicology NAS/NRC. Scientific Frontiers in Developmental Toxicology and Risk Assessment 2000, National Research Council, Washington, DC, pp. 10-25.
10. Cordier S. Evidence for a role of paternal exposures in developmental toxicity. Basic Clin Pharmacol Toxicol 2008, 102:176-181.
11. Elias S.G., van Noord P.A., Peeters P.H., et al. Childhood exposure to the 1944-1945 Dutch famine and subsequent female reproductive function. Hum Reprod 2005, 20:2483-2488.
12. Federal Register 2008, https://www.federalregister.gov/articles/2008/05/29/E8-11806/content-and-format-of-labeling-for-human-prescription-drug-and-biological-products-requirements.
13. Fisher J.S. Environmental anti-androgens and male reproductive health: focus on phthalates and testicular dysgenesis syndrome. Reproduction 2004, 127:305-315.
14. Friedman J.M. Implications of research in male-mediated developmental toxicity to clinical counsellors, regulators, and occupational safety officers. Adv Exp Med Biol 2003, 518:219-226.
15. Garbis-Berkvens J.M., Peters P.W.J. Comparative morphology and physiology of embryonic and fetal membranes. Pharmacokinetics in teratogenesis 1987, Vol. I:13-44. CRC Press, Boca Raton.
16. Gonser M., Stoll P., Kahle P. Clearance prediction and drug dosage in pregnancy. A clinical study on metildigoxin, and application to other drugs with predominant renal elimination. Clin Drug Invest 1995, 9:197-205.
17. Gregg N.M. Congenital cataract following German measles in mother. Trans Ophthalmol Soc Aust 1941, 3:35-46.
18. Hale F. Pigs born without eyeballs. J Hered 1933, 24:105-106.
19. Juchau M.R. Bioactivation in chemical teratogenesis. Ann Rev Pharmacol Toxicol 1989, 29:165-187.
20. Källén B. Epidemiology of Human Reproduction 1988, CRC Press, Boca Raton.
21. Kalter H. Teratology in the Twentieth Century and Plus Ten 2010, Springer, New York.
22. Kalter H., Warkany J. Congenital malformations. N Eng J Med 1983, 308:424-431. 491-7.
23. Kelsey F.O. Thalidomide update: regulatory aspects. Teratology 1988, 38:221-226.
24. Lander C.M., Smith M.T., Chalk J.B., et al. Bioavailability in pharmacokinetics of phenytoin during pregnancy. Eur J Clin Pharmacol 1984, 27:105-110.
25. Lenz W. Kindliche Fehlbildungen nach Medikament während der Gravidität?. Dtsch Med Wochenschr 1961, 86:2555-2556.
26. Lenz W. Thalidomide and Congenital Abnormalities. Lancet January 1962, 6:45.
27. Lenz W. A Short History of Thalidomide Embryopathy. Teratology 1988, 38:203-215.
28. Loebstein R., Lalkin A., Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 1997, 33:328-343.
29. Logan S., Price L. Infectious disease in pregnancy. Obstet Gynaec Reprod Med 2011, 21(12):331-338.
30. McBride W.G. Thalidomide and congenital abnormalities. Lancet 1961, ii:1358.
31. Miller R.K. Does the placenta protect against insult or is it the target?. Teratology Primer 2010, 9-14. Teratology Society, Reston, VA.
32. Nelson K., Holmes L.B. Malformations due to presumed spontaneous mutations in newborn infants. N Engl J Med 1989, 320:19-23.
33. Painter R.C., Roseboom T.J., Bleker O.P. Prenatal exposure to the Dutch famine and disease in later life: an overview. Reprod Toxicol 2005, 20:345-352.
34. Chr Rösch Aufgaben, Funktionen und Entwicklungperspektiven eines populationsbezogenen Fehlbildungsregisters in Deutschland (Habilitationsschrift - PhD thesis). Magdeburg 2003.
35. Sallmén M., Liesivuori J., Taskinen H., et al. Time to pregnancy among the wives of Finnish greenhouse workers. Scand J Work Environ Health 2003, 29:85-93.
36. Schaefer C. Drug Safety in Pregnancy - Utopia or achievable prospect? Risk information, risk research, advocacy in Teratology Information Services. Congenit Anom (Kyoto) 2011, 51:6-11.
37. Shepard T.H. Letter: "proof" of teratogenicity. Teratology 1994, 50:97.
38. Stephens T., Brynner R. Dark Remedy: the impact of thalidomide and its survival as a vital medicine 2009, Basic Books, New York.
39. St Clair D., Xu M., Wang P., et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. J Am Med Assoc 2005, 294:557-562.
40. Storgaard L., Bonde J.P., Olsen J. Male reproductive disorders in humans and prenatal indicators of estrogen exposure; a review of published epidemiological studies. Reprod Toxicol 2006, 21:4-15.
41. Strömland K., Nordin V., Miller M., Akerström B., Gillberg C. Autism in thalidomide embryopathy: a population. Study. Dev. Med. Child Neurol 1994, 36:251-256.
42. Wiedemann H.R. Hinweis auf eine derzeitige, Häufung hypo-und aplastischer Fehlbildunger der Gliedmassen. Med Welt 1961, 37:1863-1866.
43. Wilson J.D. Embryotoxicity of drugs to man. Handbook of Teratology 1977, Vol. 1. Plenum Press, New York, pp. 309-55.
44. Reprotox: Information database on environmental hazards to human reproduction and development. Reproductive Toxicology Center (RTC), 7831 Woodmont Ave, #375, Bethesda, MD 20814; telephone: +1 301/514-3081; Internet: . http://reprotox.org.
45. Teris: Teratogen Information System and the on-line version of Shepard's Catalog of Teratogenic Agents. University of Washington, TERIS Project, CHDD, Rm. 207 S. Bldg., Box 357920, Seattle WA 98195-7920. Fax +1-206/543-7921, Email: ; Internet: . http://depts.washington.edu/terisweb/teris/.
46. Bumps: Bumps (best use of medicines in pregnancy) - Evidence based information leaflets for women and their families on the fetal effects of specific medicines and chemicals, written by the UK Teratology Information Service: . http://www.medicinesinpregnancy.org.